Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6533
    +0.0010 (+0.15%)
     

  • OIL

    83.85
    +0.28 (+0.34%)
     

  • GOLD

    2,346.20
    +3.70 (+0.16%)
     

  • Bitcoin AUD

    97,356.13
    -1,725.83 (-1.74%)
     

  • CMC Crypto 200

    1,325.02
    -71.51 (-5.12%)
     

  • AUD/EUR

    0.6106
    +0.0033 (+0.54%)
     

  • AUD/NZD

    1.0992
    +0.0034 (+0.31%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,754.15
    +323.65 (+1.86%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,310.33
    +224.53 (+0.59%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research
·2-min read

Investors focused on the Medical space have likely heard of Regeneron Pharmaceuticals (REGN), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Regeneron Pharmaceuticals is one of 901 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. REGN is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for REGN's full-year earnings has moved 18.12% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

ADVERTISEMENT

Based on the latest available data, REGN has gained about 61.99% so far this year. Meanwhile, stocks in the Medical group have gained about 1.48% on average. This means that Regeneron Pharmaceuticals is outperforming the sector as a whole this year.

Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, which includes 393 individual stocks and currently sits at #122 in the Zacks Industry Rank. On average, stocks in this group have gained 5.12% this year, meaning that REGN is performing better in terms of year-to-date returns.

REGN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research